EU Approves Novo Nordisk's Higher-Dose Wegovy for Obesity Patients

Key Takeaways Novo Nordisk secured EU approval for a 7.2 mg once-weekly Wegovy dose for obesity patients.STEP UP data showed 20.7% weight loss at 72 weeks with 7.2 mg vs 17.5% for 2.4 mg.About 33.2% on Wegovy 7.2 mg lost at least 25% weight. Safety matched the 2.4 mg profile.Novo Nordisk (NVO) announced that the European Commission (EC) has approved a new 7.2 mg once-weekly maintenance dose of Wegovy (semaglutide injection) for adults with obesity. This provides physicians with an additional treatment optio ...